Page last updated: 2024-09-23

2',3'-dideoxyadenosine 5'-phosphate

Cross-References

ID SourceID
PubMed CID65356
CHEMBL ID1162296
SCHEMBL ID285262
MeSH IDM0055382

Synonyms (21)

Synonym
ddamp
nsc615566
107132-15-0
[(2s,5r)-5-(6-aminopurin-9-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate
2',3-dideoxyadenosine 5'-monophosphate
[(2s,5r)-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
CHEMBL1162296 ,
2',3'-dideoxyadenosine 5'-phosphate
26315-32-2
2',3'-dideoxyadenosine monophosphate
5'-adenylic acid, 2',3'-dideoxy-
SCHEMBL285262
bdbm50478976
2',3'-dideoxyadenosine 5'-monophosphate
2DA ,
2',3'-dideoxyadenosine-5'-monophosphate
[(2s,5r)-5-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate
Q27452910
((2s,5r)-5-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate
[5-(6-amino-9h-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
DTXSID60910237

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd0.10000.00062.40599.8000AID341978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.25000.00091.30738.0000AID341977; AID341992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID341992Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341978Binding affinity to ternary complex of HIV1 reverse transcriptase with primer/template in presence of dCTP substrate2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341977Inhibition of HIV1 reverse transcriptase assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341976Inhibition of HIV1 reverse transcriptase assessed as dCTP level required to form 50% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341991Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 50% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID1865852Prodrug conversion in inactivated fetal calf serum with RPMI 1640 culture medium assessed as parent ddA formation at 0.00005 M measured at 50 to 150 hrs by HPLC analysis
AID1865859Prodrug conversion in human CEM-SS cell extract assessed as parent ddA formation at 0.00005 M measured at 50 to 150 hrs by HPLC analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's6 (46.15)18.2507
2000's5 (38.46)29.6817
2010's0 (0.00)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]